Claims for Patent: 5,989,885

Summary for Patent: 5,989,885

Title:	Specific mutations of map kinase 4 (MKK4) in human tumor cell lines identify it as a tumor suppressor in various types of cancer
Abstract:	The present invention relates to mutations in the MKK4 gene in human cancers and their use in the diagnosis and prognosis of human cancer. Specific mutations in the MKK4 gene which are associated with breast, pancreatic, colorectal and testicular cancers have been identified. The invention also relates to the therapy of human cancers which have a mutation in the MKK4 gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.
Inventor(s):	Teng; David H. -F. (Salt Lake City, UT), Tavtigian; Sean V. (Salt Lake City, UT), Perry, III; William L. (Salt Lake City, UT), Skolnick; Mark H. (Salt Lake City, UT)
Assignee:	Myriad Genetics, Inc. (Salt Lake City, UT)
Application Number:	08/874,186
Patent Claims:	1. An isolated DNA consisting any one of the DNAs having a sequence in the group consisting of SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45 and SEQ ID NO:46. 2. An isolated DNA comprising 13 nucleotides selected from the group consisting of: (a) DNA defined by SEQ ID NO:40 having a T at nucleotide 285 wherein said isolated DNA consists of a fragment of SEQ ID NO:40 and includes the T at nucleotide 285; (b) DNA defined by SEQ ID NO:41 having a T at nucleotide 421 wherein said isolated DNA consists of a fragment of SEQ ID NO:41 and includes the T at nucleotide 421; (c) DNA defined by SEQ ID NO:43 having a G at nucleotide 117 wherein said isolated DNA consists of a fragment of SEQ ID NO:43 and includes the G at nucleotide 117; (d) DNA defined by SEQ ID NO:43 having a A at nucleotide 136 wherein said isolated DNA consists of a fragment of SEQ ID NO:43 and includes the A at nucleotide 136; (e) DNA defined by SEQ ID NO:44 having a C at nucleotide 1066 wherein said isolated DNA consists of a fragment of SEQ ID NO:44 and includes the C at nucleotide 1066. 3. A replicative cloning vector which comprises the isolated DNA of claim 2 and a replicon operative in a host cell. 4. An expression system which comprises the isolated DNA of claim 2 operably linked to suitable control sequences. 5. Recombinant host cells transformed with the replicative cloning vector of claim 3. 6. Recombinant host cells transformed with the expression system of claim 4. 7. A nucleic acid probe complementary to human altered MKK4 gene sequences wherein said nucleic acid probe hybridizes to a mutant MKK4 gene under hybridization conditions which prevent hybridizing of said nucleic acid probe to a wild-type MKK4 gene wherein said mutant MKK4 gene is selected from the group consisting of: (a) a mutant MKK4 gene having a T at the nucleotide corresponding to base number 285 of SEQ ID NO:40; (b) a mutant MKK4 gene having a T at the nucleotide corresponding to base number 421 of SEQ ID NO:41; (c) a mutant MKK4 gene having a G at the nucleotide corresponding to base number 117 of SEQ ID NO:43; (d) a mutant MKK4 gene having an A at the nucleotide corresponding to base number 136 of SEQ ID NO:43; and (e) a mutant MKK4 gene having a C at the nucleotide corresponding to base number 1066 of SEQ ID NO:44. 8. A pair of single-stranded DNA primers wherein use of said primers in a polymerase chain reaction results in amplication of a MKK4 gene fragment, wherein the sequence of said primers is derived from the intron regions of any one of the DNAs defined by SEQ ID NO: 36-46. 9. An isolated DNA comprising bases 21-1217 of SEQ ID NO:91 wherein said DNA contains a mutation selected from the group consisting of: (a) a T at nucleotide 571; (b) a T at nucleotide 681; (c) a G at nucleotide 840; (d) an A at nucleotide 859; and (e) a C at nucleotide 947.

Details for Patent 5,989,885

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2017-01-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2017-01-10
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2017-01-10